RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024

Written By Michael Gary Scott







Analysis: Reviva Pharmaceuticals Surpasses Analyst Estimates in Q1 2024

Strong Start for Reviva Pharmaceuticals

RVPH stock - RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024

Source: iQoncept / Shutterstock

Reviva Pharmaceuticals (NASDAQ:RVPH) recently announced its results for Q1 2024.

  • Reviva Pharmaceuticals exceeded expectations by reporting earnings per share of -25 cents, surpassing the anticipated -42 cents.
  • The company did not disclose any revenue figures for the quarter.

It seems like Reviva Pharmaceuticals is off to a promising start in 2024, outshining the predictions set by analysts.


Stay tuned for further updates on Reviva Pharmaceuticals as the year progresses.


See also  Ultra-High-Yield Dividend Stocks on the Rise Profitable Potential in Ultra-High-Yield Dividend Stocks: Analysts' Insight